This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pet Food Lawsuit Won't Neuter Wall Street

Stocks in this article: BCS KKR FDP

NEW YORK ( TheStreet) - A settlement involving Barclays Capital (BCS) and Del Monte Foods' over its pet food business sale is being described by lawyers as leading to "sweeping change" in investment banking, but longtime industry watchers think it will be much harder to teach old Wall Street dogs new tricks.

On Thursday, a Delaware judge accepted an October settlement with Del Monte shareholders over a dispute arising from a buyout of the company's pet foods division in 2010. The deal finalizes an $89.4 million settlement brokered by the Delaware court that the two parties acted improperly in a sale of the business to a consortium of private equity investors led by KKR (KKR - Get Report).

Some shareholders sued Del Monte and Barclays citing a potential conflict when the bank financed the debt needed for private equity investors to buy the California -based maker of Meow Mix and Milk Bone pet foods for $5.3 billion, while also advising the board on sale negotiations.

Earlier in the year, Delaware Chancery Court, Judge Travis Laster ruled in favor of plaintiffs citing Barclays' lack of disclosure, and Thursday ruled that the $89.4 million settlement "provides excellent consideration" to Del Monte shareholders, who will also get an additional 50 cents to the company's $19 a share buyout.

According to October filings with the Securities and Exchanges Commission, Barclays Capital and Del Monte Foods will split a $89.4 million payment by sending $23.7 million and $65.7 million respectively to Del Monte Foods shareholders. Upon the settlement both companies denied all wrongdoing.

The settlement alone, at first glance, appears to have stopped Wall Street in its tracks in a still lucrative but conflict-prone activity, just as legislation like the Dodd Frank Act cut at other often profitable revenue streams like proprietary trading.

Grant & Eisenhofer, the plaintiffs lawyers said on its Web site that "the lawsuit, which challenged the common practice by many deal advisers to simultaneously offer sell-side financing in a transaction, led to sweeping changes in the way investment banks conduct business in the M&A marketplace."

Nevertheless, deal watchers see that over time, Wall Street will return to its old habits, albeit reformed.

Calling the settlement "very unusual and significant in size," Jeffrey N. Gordon of Columbia Law School maintains of potential investment bank conflicts in providing financing and advice, "so long as this is disclosed to a sellers board and so long as an impartial fairness opinion is given, I think the practice called staple financing can be managed." The net result of the settlement may simply be better disclosure by investment banks in their M&A work, says Gordon.

About the settlement, John Coates of Harvard Law School asks, 'is it temporary attention, or will it change practices over a long period of time?" Since the Delaware court ruling hinged on Barclays' disclosure and not its actual investment banking practice, Coates believes in the former.

It signals that after a retreat in providing staple financing, investment banks may one day return to the practice when better able to manage potential conflicts.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,312.88 -103.97 -0.60%
S&P 500 2,010.74 -10.51 -0.52%
NASDAQ 4,679.7960 -3.6110 -0.08%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs